Platinol-AQ Interactions
There are 438 drugs known to interact with Platinol-AQ (cisplatin), along with 7 disease interactions. Of the total drug interactions, 87 are major, 332 are moderate, and 19 are minor.
- View all 438 medications that may interact with Platinol-AQ
- View Platinol-AQ disease interactions (7)
Most frequently checked interactions
View interaction reports for Platinol-AQ (cisplatin) and the medicines listed below.
- Actemra (tocilizumab)
- Amicar (aminocaproic acid)
- Aricept (donepezil)
- Avastin (bevacizumab)
- Banzel (rufinamide)
- Baraclude (entecavir)
- Blincyto (blinatumomab)
- Cresemba (isavuconazonium)
- Cymbalta (duloxetine)
- Diflucan (fluconazole)
- Epidiolex (cannabidiol)
- Farydak (panobinostat)
- Imbruvica (ibrutinib)
- Imlygic (talimogene laherparepvec)
- Isentress (raltegravir)
- Jadenu Sprinkle (deferasirox)
- Kalydeco (ivacaftor)
- Lamictal (lamotrigine)
- midazolam
- Natrecor (nesiritide)
- Ofev (nintedanib)
- Orencia (abatacept)
- Pegasys (peginterferon alfa-2a)
- Pomalyst (pomalidomide)
- Prolixin (fluphenazine)
- Ravicti (glycerol phenylbutyrate)
- Sabril (vigabatrin)
- Soliris (eculizumab)
- Sporanox (itraconazole)
- Sprycel (dasatinib)
Platinol-AQ disease interactions
There are 7 disease interactions with Platinol-AQ (cisplatin) which include:
- infections
- hearing loss
- myelosuppression
- peripheral neuropathy
- renal dysfunction
- hemolytic anemia
- ocular toxicity
Report options
QR code containing a link to this page
More about Platinol-AQ (cisplatin)
- Platinol-AQ consumer information
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: alkylating agents
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
